In the rapidly evolving biosimilar landscape, regulatory approval remains a critical challenge for manufacturers seeking to bring these complex products to market. What strategies are most effective when preparing for FDA meetings? How can developers best demonstrate biosimilarity through analytical characterization, clinical study design, and interchangeability data? This webinar will address key regulatory considerations—providing practical guidance on FDA expectations, common submission pitfalls, and successful approaches to navigate the approval pathway from development through commercialization.

Subject area:
Biologics

Objectives (If applicable):
N/A

Target Audience (If applicable):
Drug manufacturing, pharmaceutical manufacturing, biomanufacturing, biologics organizations; Job function: process design, quality assurance (QA), quality control (QC), operations managers, quality management, pharmaceutical quality directors, MHA, MPH.